Clinical trial
A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults
NCT03699241 is registered in ClinicalTrials.gov with International AIDS Vaccine Initiative as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults
- Lead sponsor
- International AIDS Vaccine Initiative
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 3, 2018
- Completion date
- July 11, 2023
- Enrollment
- 61 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.